Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00272480
Status:
COMPLETED
Last Update Posted:
2021-08-25
First Post:
2006-01-04
Brief Title:
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy a Randomised Trial
Sponsor:
Imperial College London
Organization:
Imperial College London
Study Overview
Official Title:
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy a Randomised Trial
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I
Detailed Description:
Randomised double-blind placebo-controlled two centre study of zidvoudine plus lamivudine in HAMTSP 24 patients randomised 11 2-4 week lead-in 6 months randomised phase followed by 6 months open-label therapy with active drug Primary endpoint clinical Secondary endpoints virological and immunological
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None